TORONTO, ONTARIO--(Marketwired - June 30, 2015) - Bradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) announced today that its letter of intent with XORTX Pharma Corp. relating to a proposed business combination has been terminated. The proposed transaction was initially announced by Bradmer on November 18, 2014 and trading of the common shares of Bradmer has been halted since that date. It is anticipated that the common shares of Bradmer will resume trading on the NEX Board of the TSX Venture Exchange on or about July 6, 2015.
The directors and officers of Bradmer intend to seek out new opportunities considered to be in the best interests of Bradmer and its shareholders.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Bradmer Pharmaceuticals Inc.
Paul Van Damme